Astra USA, Inc. v. Santa Clara County
The Supreme Court ruled that local health clinics receiving discounted drugs under a federal program cannot sue drug manufacturers directly for overcharging, even by claiming to be beneficiaries of the manufacturers' pricing contracts with the government.
Because those contracts simply restate the same price ceilings set by federal law, letting clinics sue on the contracts would be the same as letting them sue under the statute itself -- something Congress never allowed, leaving enforcement solely with the federal health agency.
“We hold that suits by 340B entities to enforce ceiling-price contracts running between drug manufacturers and the Secretary of HHS are incompatible with the statutory regime.”
The Court's core holding that clinics cannot sue manufacturers over the pricing agreements.
How it got here: A federal trial court dismissed the county's suit; the Ninth Circuit reversed, allowing the suit to proceed; the drug companies asked the Supreme Court to review that ruling.
The Case in Depth
What happened
A federal law caps the prices drug manufacturers can charge public hospitals and community clinics that serve the poor. Manufacturers sign a standard pricing agreement with the government to take part in this discount program. Santa Clara County, which runs several such clinics, sued Astra and other drug companies, claiming the companies overcharged the clinics in violation of those pricing agreements.
The question before the Court
Could a county that runs discount-drug clinics sue drug companies directly for overcharging, by claiming rights under the companies' price agreements with the federal government?
Why it matters
Public hospitals and community health centers that rely on discounted drug pricing cannot go to court on their own when they believe a drug company overcharged them; they must instead rely on the federal Health Resources and Services Administration to investigate and resolve complaints, a process Congress recently required the agency to formalize.
What changes now
The Ninth Circuit's ruling allowing the county's lawsuit is reversed, ending this case. Going forward, clinics with overcharge complaints must rely on the federal health agency's dispute-resolution process, which Congress directed be formalized under the 2010 health-care law, with any resulting agency decision reviewable in court under ordinary administrative-law standards rather than through a private breach-of-contract suit.
What this does not decide
The Court did not decide whether a government contracting agency could ever authorize third-party lawsuits to enforce a government contract, nor did it address a separate dispute over whether federal law bars state-law fraud claims regarding drug price reporting; both were left open.
How the Court got there
The legal reasoning, step by step
- The Court began from the undisputed premise that Congress gave clinics no right to sue drug manufacturers directly under the discount-pricing statute itself, leaving enforcement to the federal health agency.
- The Court then asked whether the clinics could get around that limit by suing instead as 'third-party beneficiaries' of the manufacturers' pricing agreements with the government -- a doctrine that lets someone who benefits from a contract enforce it even though they didn't sign it.
- The Court found that the pricing agreements were not negotiated contracts but standard forms that simply restated the same price ceilings already required by the statute, with no independent terms of their own.
- Because the agreements added nothing beyond what the statute already required, the Court reasoned that a lawsuit to enforce the agreements was really just a lawsuit to enforce the statute wearing different clothing.
- The Court also weighed practical concerns: allowing thousands of clinics to sue individually could produce inconsistent rulings and would undercut the federal agency's ability to run the discount program and a related Medicaid rebate program consistently nationwide, especially since manufacturers' confidential pricing data is protected from disclosure.
- Concluding that private suits were incompatible with Congress's chosen enforcement structure, the Court held that clinics may not sue manufacturers as third-party beneficiaries of the pricing agreements.